BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 31286200)

  • 1. Radiomic features of glucose metabolism enable prediction of outcome in mantle cell lymphoma.
    Mayerhoefer ME; Riedl CC; Kumar A; Gibbs P; Weber M; Tal I; Schilksy J; Schöder H
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2760-2769. PubMed ID: 31286200
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pre-Therapeutic Total Lesion Glycolysis on [
    Mayerhoefer ME; Staudenherz A; Kiesewetter B; Weber M; Simonitsch-Klupp I; Gibbs P; Dolak W; Lukas J; Raderer M
    Mol Imaging Biol; 2019 Dec; 21(6):1192-1199. PubMed ID: 30847823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in mantle cell lymphoma.
    Albano D; Bosio G; Bianchetti N; Pagani C; Re A; Tucci A; Giubbini R; Bertagna F
    Ann Nucl Med; 2019 Jul; 33(7):449-458. PubMed ID: 30929200
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of metabolic tumour volume on baseline
    Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
    Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of outcome in anal squamous cell carcinoma using radiomic feature analysis of pre-treatment FDG PET-CT.
    Brown PJ; Zhong J; Frood R; Currie S; Gilbert A; Appelt AL; Sebag-Montefiore D; Scarsbrook A
    Eur J Nucl Med Mol Imaging; 2019 Dec; 46(13):2790-2799. PubMed ID: 31482428
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of Overall Survival and Progression-Free Survival by the
    Zhou Y; Ma XL; Pu LT; Zhou RF; Ou XJ; Tian R
    Contrast Media Mol Imaging; 2019; 2019():5963607. PubMed ID: 31777473
    [No Abstract]   [Full Text] [Related]  

  • 7. Prognostic role of baseline
    Albano D; Bosio G; Camoni L; Farina M; Re A; Tucci A; Giubbini R; Bertagna F
    Hematol Oncol; 2019 Feb; 37(1):39-46. PubMed ID: 30299563
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [
    Vergote VKJ; Verhoef G; Janssens A; Woei-A-Jin FJSH; Laenen A; Tousseyn T; Dierickx D; Deroose CM
    Leuk Lymphoma; 2023 Jan; 64(1):161-170. PubMed ID: 36223113
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A pilot study for texture analysis of
    Nakajo M; Kajiya Y; Tani A; Jinguji M; Nakajo M; Kitazono M; Yoshiura T
    Eur J Nucl Med Mol Imaging; 2017 Dec; 44(13):2158-2168. PubMed ID: 28770274
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Usefulness of Machine Learning-Based Evaluation of Clinical and Pretreatment [
    Nakajo M; Kawaji K; Nagano H; Jinguji M; Mukai A; Kawabata H; Tani A; Hirahara D; Yamashita M; Yoshiura T
    Mol Imaging Biol; 2023 Apr; 25(2):303-313. PubMed ID: 35864282
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [18F]FDG-PET/CT Radiomics for Prediction of Bone Marrow Involvement in Mantle Cell Lymphoma: A Retrospective Study in 97 Patients.
    Mayerhoefer ME; Riedl CC; Kumar A; Dogan A; Gibbs P; Weber M; Staber PB; Huicochea Castellanos S; Schöder H
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32370121
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ability of
    Ou X; Wang J; Zhou R; Zhu S; Pang F; Zhou Y; Tian R; Ma X
    Contrast Media Mol Imaging; 2019; 2019():4507694. PubMed ID: 30930700
    [No Abstract]   [Full Text] [Related]  

  • 13. Prognostic modeling for patients with colorectal liver metastases incorporating FDG PET radiomic features.
    Rahmim A; Bak-Fredslund KP; Ashrafinia S; Lu L; Schmidtlein CR; Subramaniam RM; Morsing A; Keiding S; Horsager J; Munk OL
    Eur J Radiol; 2019 Apr; 113():101-109. PubMed ID: 30927933
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiomics based on
    Ou X; Zhang J; Wang J; Pang F; Wang Y; Wei X; Ma X
    Cancer Med; 2020 Jan; 9(2):496-506. PubMed ID: 31769230
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic Value of Heterogeneity Index Derived from Baseline
    Liu F; Gu B; Li N; Pan H; Chen W; Qiao Y; Song S; Liu X
    Front Oncol; 2022; 12():862473. PubMed ID: 35494037
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and validation of an
    Wang H; Zhao S; Li L; Tian R
    Eur Radiol; 2020 Oct; 30(10):5578-5587. PubMed ID: 32435928
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Robustness of Radiomic Features in [
    Lu L; Lv W; Jiang J; Ma J; Feng Q; Rahmim A; Chen W
    Mol Imaging Biol; 2016 Dec; 18(6):935-945. PubMed ID: 27324369
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
    Wu LL; Liang JH; Wang L; Xu W; Ding CY
    Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
    [No Abstract]   [Full Text] [Related]  

  • 19. Is there a role for therapy response assessment with 2-[fluorine-18] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in mantle cell lymphoma?
    Kedmi M; Avivi I; Ribakovsky E; Benyamini N; Davidson T; Goshen E; Tadmor T; Nagler A; Avigdor A
    Leuk Lymphoma; 2014 Nov; 55(11):2484-9. PubMed ID: 24432895
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Performance of baseline FDG-PET/CT radiomics for prediction of bone marrow minimal residual disease status in the LyMa-101 trial.
    Bodet-Milin C; Morvant C; Carlier T; Frecon G; Tournilhac O; Safar V; Kraeber-Bodere F; Le Gouill S; Macintyre E; Bailly C
    Sci Rep; 2023 Oct; 13(1):18177. PubMed ID: 37875524
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.